ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE

Formes cristallines anhydres de n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide

Abstract

L'invention concerne (1) des formes cristallines anhydres de N-[1 -(2-éthoxyéthyl)-5-(N-éthyl-N-méthylamino)-7-(4-méthylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3- carbonyl]méthanesulfonamide, (2) des compositions pharmaceutiques comprenant au moins une telle forme, (3) des procédé de traitement d'un état à médiation par phosphodiestérase-5 mettant en oeuvre au moins une telle forme et (4) des procédés de préparation de telles formes.
The invention comprises (1) anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide, (2) pharmaceutical compositions comprising at least one such form, (3) methods for the treatment of a phosphodiesterase-5-mediated condition using at least one such form, and (4) methods for preparing such forms. The compound N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide has the following structure (I).

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (3)

    Publication numberPublication dateAssigneeTitle
    WO-0210171-A1February 07, 2002Pfizer Limited, Pfizer Inc.Crystalline therapeutic agent
    WO-2004096810-A1November 11, 2004Pfizer Limited, Pfizer Inc.5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
    WO-2005049616-A1June 02, 2005Pfizer Limited, Pfizer Inc.5,7-diaminopyrazolo[4,3-d]pyrimidines a effet inhibiteur par rapport a la pde-5

NO-Patent Citations (0)

    Title

Cited By (0)

    Publication numberPublication dateAssigneeTitle